Related Experiment Video
Updated: Oct 4, 2025
05:16
Cutoff Value of Phase Angle by Bioelectrical Impedance Analysis at Admission as a Prognostic Factor in Patients with Acute Heart Failure
Published on: June 10, 2025
273
Interactions Between Atrial Fibrillation and Natriuretic Peptide in Predicting Heart Failure Hospitalization or
Paul F Brady1,2,3, Winnie Chua1, Frantisek Nehaj1,2,4
1Institute of Cardiovascular Sciences College of Medical and Dental Sciences University of Birmingham Birmingham UK.
Journal of the American Heart Association
|February 3, 2022
Summary
Elevated N-terminal pro-B-type natriuretic peptide (NT-proBNP) levels predict future heart failure (HF) events in patients with atrial fibrillation (AF), even without HF. Routine NT-proBNP measurement is recommended for assessing patients with AF.
Area of Science:
- Cardiology
- Biomarkers
- Clinical Prediction
Background:
- Natriuretic peptides are standard for diagnosing heart failure (HF).
- Elevated natriuretic peptide concentrations are also observed in atrial fibrillation (AF).
- The predictive value of these peptides for cardiovascular events in patients with AF and/or HF requires clarification.
Purpose of the Study:
- To assess the role of N-terminal pro-B-type natriuretic peptide (NT-proBNP) in predicting cardiovascular outcomes.
- To correlate NT-proBNP levels with the presence of AF and HF.
- To evaluate NT-proBNP's prognostic value across different patient phenotypes.
Main Methods:
- Consecutive patients with cardiovascular conditions underwent clinical assessment, 7-day ECG monitoring, and echocardiography.
- NT-proBNP levels were centrally quantified and categorized into four groups.
- Outcomes (HF hospitalization or cardiovascular death) were tracked over a median of 2.5 years.
Main Results:
- Cardiovascular event rates increased significantly with the presence of AF and/or HF.
- Higher NT-proBNP concentrations were strong predictors of outcomes in patients with AF only (C-statistic, 0.82) and in those with both AF and HF (C-statistic, 0.66).
- NT-proBNP predicted future HF events in patients with AF, regardless of concurrent HF diagnosis.
Conclusions:
- Elevated NT-proBNP concentrations are significant predictors of future cardiovascular events in patients with AF.
- Routine NT-proBNP quantification is valuable for assessing cardiovascular risk in patients with AF.
- These findings support the use of NT-proBNP in managing patients with AF and cardiovascular conditions.
Related Concept Videos
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
550
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
550
01:29Heart Failure II: Pathophysiology
91
Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
91
01:22Heart Failure Drugs: Diuretics
519
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
519
01:30Heart Failure V: Medical Management
39
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
39
01:22Heart Failure Drugs: β-Blockers
460
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
460
01:19Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers
250
Cardiac biomarkers are critical in diagnosing, prognosing, and managing cardiovascular diseases. Routine measurement of specific biomarkers such as B-type natriuretic peptide (BNP), C-reactive protein (CRP), and homocysteine (Hcy) is common practice in clinical settings to evaluate heart function and predict cardiovascular events.
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
250